The healthcare-products company is taking another shot at resolving mass cancer lawsuits in chapter 11 after two failed ...

The Biden administration’s drug-price negotiation law threatens new product development and will lead to fewer new medicines ...

A state judge in Oregon has overturned a $260 million verdict against Johnson & Johnson in a mesothelioma lawsuit. The judge ...

In a report released today, Joanne Wuensch from Citi reiterated a Buy rating on Johnson & Johnson (JNJ – Research Report). The ...

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II drugs for Lupus Nephritis have a 50% phase transition ...

Iowa star RB Kaleb Johnson discusses the significance of Iowa's win over Minnesota, especially after last season's loss to ...

Iowa RB Kaleb Johnson recorded a career-high 206 yards and three touchdowns to help lead Iowa to a 31-14 victory over ...

Johnson & Johnson (JNJ) closed the most recent trading day at $166.61, moving +1.36% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.16%. At the same time, the Dow ...

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Soft Tissue Sarcoma.

Johnson Controls (NYSE: JCI), the global leader for smart, healthy and sustainable buildings, is showcasing its industry ...

As rates fall after the Fed's September meeting, experts say it's a good time to look at large, financed purchases and ...

The pro dancer also previews her partnership with Joey Graziadei, saying the Bachelor is 'humble and hardworking.' ...